pharmaphorum

Amgen's Repatha cardio data fails to impress

Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...
Morningstar

Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...
Nasdaq

Amgen's Repatha Cuts Cardiovascular Risk By Up To 36% In Phase 3 Trial

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
STAT

Amgen’s cholesterol shot prevented first heart attacks and strokes, more detailed data affirm

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...
Pharm Exec

Amgen Launches New Direct-To-Patient Program AmgenNow

AmgenNow, a direct-to-patient program, launches with Repatha, following positive Phase III Vesalius-CV trial results showing reduced cardiovascular events. Starting October 6, 2025, AmgenNow will be ...
Seeking Alpha

Amgen to offer Repatha at 60% discount to U.S. consumers

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...
Healio

Repatha made available via direct-to-patient program at discounted price

Please provide your email address to receive an email when new articles are posted on . Evolocumab will be made available to eligible patients via a new direct-to-consumer program. The PCSK9 inhibitor ...
MarketWatch

Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...
Investing

Amgen’s Repatha reduces cardiovascular events in primary prevention study

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent player in the biotechnology industry with a market capitalization of $160.7 billion, announced Thursday that its Phase 3 VESALIUS-CV clinical ...
STAT

Amgen says its cholesterol shot prevented heart problems in a broad population

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...
WebMD

What Is Repatha, and Why Does It Matter?

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...